CA-INSEEGO
31.3.2021 15:07:07 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and IoT device-to-cloud solutions, today announced that its Wavemaker PRO 5G indoor router FX2000e has been certified for use in several markets globally. This plug-and-play fixed wireless solution provides 5G/LTE broadband with ethernet and Wi-Fi 6 connectivity for up to 32 devices, making it ideal for small businesses and distributed employees who need fast, reliable and highly secure internet access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005341/en/
With gigabit-class 5G speeds, the FX2000e delivers fast, reliable connectivity almost anywhere, from restaurant and retail locations to branch offices and home offices. The Inseego Mobile app provides an intuitive UI and makes it easy for end users to self-install their devices. Using Inseego Connect cloud softwarei , IT managers can remotely configure and manage all devices in a highly scalable deployment.
“5G solutions provide a great choice for broadband access for businesses and consumers in their distributed offices and homes,” said Inseego President of IoT & Mobile Solutions Ashish Sharma. “Our FX2000e is a compact solution that supports many different use cases for broadband connectivity: Small businesses can get fast internet access anywhere. Enterprises can easily deploy a secure WAN solution for their branch offices and remote employees. And SD WAN providers can now rely on a 5G WAN connection as a primary broadband connection for distributed locations.”
Flexible 5G connectivity
The FX2000e is certified to operate in a broad range of global 5G and 4G frequency bands. Designed as a powerful and cost-effective solution for last-mile internet access, it can bring high-speed broadband connectivity to users on leading 4G and 5G networks in global markets.
With its small form factor, the FX2000e can be deployed as the primary broadband solution for distributed retail locations, as an add-on WAN interface for SD WAN deployments, as an internet solution for small occupancy homes, or as a cable modem replacement for larger homes with mesh Wi-Fi systems and other connectivity needs.
Fast, flexible, reliable and secure
- Gigabit-class 5G and LTE speeds
- Robust connectivity with ethernet and Wi-Fi 6 for up to 32 devices
- Dual-SIM functionality for up to two carrier SIMs, with auto-switching between cellular networks and ethernet WAN
- Enterprise-grade security with OpenVPN, access control, end-to-end device security, threat identification, monitoring, threat alerts and other protectionsii
- Inseego Connect™ Advanced cloud management
- Continuous software updates, security and support
Availability
The Inseego Wavemaker™ PRO 5G indoor CPE FX2000e has received regulatory certifications for use in several regions worldwide, including FCC Band 48 support for CBRS networks, and is now available through major distributors in North America and Europe. Please contact Inseego to learn more.
A broad portfolio of 5G FWA solutions for consumers and enterprise customers
In addition to the FX2000e, the Inseego Wavemaker PRO portfolio includes the 5G indoor CPE FG2000e, which is currently commercially available in several markets. The portfolio also includes two 5G outdoor CPEs and a 5G industrial gateway. Please contact Inseego to learn more about these solutions.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide. To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp.
________________
i
Base version (free) enables a user to manage a single FX2000e device settings easily using the Inseego Mobile app or Web UI. For management of multiple devices, an Inseego Connect Standard or Inseego Connect Advanced subscription is required, providing advanced device management, provisioning, monitoring, and diagnostics for multiple devices from a single dashboard.
ii Contact Inseego to learn more about available advanced security solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005341/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom